Literature DB >> 2273521

Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis.

K R Wilske1, L A Healey.   

Abstract

Traditional therapy of rheumatoid arthritis (RA) has been dominated by the therapeutic pyramid. This approach is not working. The designation of drugs as either antiinflammatory or disease modifying is not borne out by experience. We possess a number of drugs, each only partially effective against inflammation, that work by poorly understood mechanisms. Until a major breakthrough appears, it is proposed to treat RA with a combination of these medications early in the disease course, to gain control of the inflammation, and then bridge to a simplified program by withdrawing drugs sequentially.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2273521

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


  10 in total

1.  Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.

Authors:  C H van Jaarsveld; J W Jacobs; M J van der Veen; A A Blaauw; A A Kruize; D M Hofman; H L Brus; G A van Albada-Kuipers; A H Heurkens; E J ter Borg; H C Haanen; C van Booma-Frankfort; Y Schenk; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of rheumatoid arthritis: state of the art 2009.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

Review 3.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

Review 4.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Experience with low-dose methotrexate: toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis.

Authors:  M Nisar; L Carlisle; R Amos
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 6.  Combination therapy: the risks of infection and tumor induction.

Authors:  D E Yocum
Journal:  Springer Semin Immunopathol       Date:  2001

Review 7.  [Rheumatoid arthritis].

Authors:  D Aletaha; A Kerschbaumer
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

8.  The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients.

Authors:  Khalid Almutairi; Johannes Nossent; David B Preen; Helen Keen; Charles Inderjeeth
Journal:  Rheumatol Int       Date:  2021-09-18       Impact factor: 3.580

Review 9.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 10.  Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.

Authors:  Mahboob U Rahman; Jacqui Buchanan; Mittie K Doyle; Elizabeth C Hsia; Timothy Gathany; Shreekant Parasuraman; Daniel Aletaha; Eric L Matteson; Philip G Conaghan; Edward Keystone; Désireé van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2011-06-27       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.